Biogen’s (Nasdaq: BIIB) novel Alzheimer’s disease (AD) therapy is struggling to clear the launch pad, generating just $300,000 in the first quarter in which it became available.
The $56,000 annual cost, combined with ongoing uncertainty around the circumstances of its approval and the reliability of its efficacy data, have conspired to create an uphill battle for market access.
The outcome, well short of analysts’ estimations of around $10 million in sales, was announced as part of the firm’s third quarter financial results statement, which revealed overall revenues of $2.8 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze